TABLE 1.
Demographic and clinical characteristics in 322 women with community-onset complicated nonobstructive acute pyelonephritis due to Enterobacteriaceae, by treatment regimen
| Characteristica | Patients treated with: |
P value | |
|---|---|---|---|
| Cefuroxime (n = 156) | Cefotaxime (n = 166) | ||
| Age (median [1st quartile–3rd quartile]) (yr) | 71.0 (61.5–77.0) | 72.0 (63.0–77.0) | 0.407b |
| Clinical features | |||
| Body temp (median [IQR]) (°C) | 38.8 (38.2–39.4) | 38.7 (38.3–39.4) | 0.592b |
| Body temp ≥39.0°C | 60 (38.5) | 74 (44.6) | 0.266c |
| Costovertebral angle tenderness | 115 (73.7) | 81 (48.8) | 0.001c |
| Lower urinary tract infection symptoms | 93 (59.6) | 87 (52.4) | 0.193c |
| Nausea or vomiting | 63 (40.4) | 54 (32.5) | 0.143c |
| Enterobacteriaceae isolated from urine or blood | |||
| E. coli | 139 (89.1) | 146 (88.0) | |
| K. pneumoniae | 9 (5.8) | 14 (8.4) | |
| E. aerogenes | 2 (1.3) | 4 (2.4) | |
| Other | 6 (3.8) | 2 (1.2) | |
| Laboratory findings | |||
| Bacteremia | 66 (42.3) | 88 (53.0) | 0.055c |
| C-reactive protein level (median [IQR]) (mg/dl) | 11.3 (5.6–18.1) | 11.7 (5.7–19.7) | 0.455b |
| C-reactive protein level ≥15 mg/dl | 51 (32.7) | 64 (38.6) | 0.273c |
| Enterobacteriaceae resistant to cefazolin or cephradine | 39 (25.0) | 47 (28.3) | 0.502c |
| Enterobacteriaceae resistant to cefotaxime | 13 (8.3) | 23 (13.9) | 0.116c |
| Enterobacteriaceae resistant to fluoroquinolones | 31 (19.9) | 39 (23.5) | 0.431c |
| Extended-spectrum β-lactamase+ Enterobacteriaceae | 14 (9.0) | 25 (15.1) | 0.094c |
| Hematuria | 109 (69.9) | 111 (66.9) | 0.563c |
| White blood cell count (median [IQR]) (/mm3) | 11,985 (9,305–14,930) | 12,085 (8,905–14,758) | 0.623b |
| White blood cell count ≥15,000/mm3 of blood | 38 (24.4) | 39 (23.5) | 0.856c |
| Past history | |||
| Antibiotic use within 1 yr | 26/142 (18.3)d | 34/147 (19.4)d | 0.313c |
| Previous urinary tract infection history | 27/142 (19.0)d | 25/148 (16.9)d | 0.638c |
| Prior history of hospitalization within 1 yr | 27/143 (18.9)d | 34/149 (22.8)d | 0.408c |
| Underlying diseases | |||
| Cerebrovascular disorder | 6 (3.9) | 20 (12.1) | 0.007c |
| Chronic kidney disease | 7 (4.5) | 5 (3.0) | 0.485c |
| Chronic liver disease | 6 (3.9) | 9 (5.4) | 0.503c |
| Chronic pulmonary disease | 6 (3.9) | 5 (3.0) | 0.681c |
| Congestive heart failure | 5 (3.2) | 8 (4.8) | 0.462c |
| Connective tissue disorder | 4 (2.6) | 4 (2.4) | >0.999c |
| Diabetes mellitus | 68 (43.6) | 85 (51.2) | 0.172c |
| Hypertension | 62 (39.7) | 65 (39.2) | 0.914c |
| Malignancy | 9 (5.8) | 4 (2.4) | 0.126c |
| Neurogenic bladder | 6 (3.9) | 14 (8.4) | 0.088c |
| Polycystic kidney disease | 0 | 3 (1.8) | 0.248c |
| Urolithiasis | 6 (3.9) | 8 (4.8) | 0.669c |
| Vesicoureteral reflux | 1 (0.6) | 4 (2.4) | 0.372c |
a
Unless otherwise indicated, the data are shown as the number (%) of patients.
b
Mann-Whitney U test.
c
Pearson chi-square test or Fisher's exact test.
d
Denominators are the number of patients whose data were available in each group.